European Journal of Biomedical and Pharmaceutical Sciences

DEVASTATING DEPRESSION OF YOUTH AND ITS REMEDIAL DRUG: A REVIEW

Aparna Gupta, Vijay Sharma and Lalit Singh*

ABSTRACT

Depression is the most common psychiatric disorder reported in every next person in today‟s lifestyle. Depression has become the third leading cause of global disease burden, and is accounting for 4.3% of total disability-adjusted life years. If this continues for long it will become the leading cause of disease burden by the year 2030. According to a community survey the prevalence rate of depression amongst the adolescents is between 1.8%- 7.8%. The several forms of depressive disorders are found amongst, which the most common are major depressive disorder and dysthymic disorder. Amitryptyline along with a Selective Serrotonin Reuptake Inhibitor (SSRI), i.e. fluoxetine is the treatment option for depression, as per the list of essential medicines issued by the WHO. But because of the certain side-effects of SSRI‟s, it became necessary to switch on the bupropion to treat the condition of major depression. Bupropion was discovered in 1985 & is the fourth most prescribed antidepressant in the United States. The Bupropion was firstly discovered to treat the Major Depressive Disorder (MDD) and is frequently used for smoking- cessation. Bupropion is the much demanded drug among the youth. In general, youth undergoing through the phase of depression may notice an improvement in various symptoms like improved mood, improved concentration, more energy and better sleep after taking this medication.

Keywords: Depression, Depressive Disorders, Bupropion, youth depression, smoking -cessation.